- Home
- ELAB vs REVB Comparison
ELAB vs REVB Comparison
Compare ELAB & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- REVB
- Stock Information
- Founded
- ELAB 2020
- REVB 2020
- Country
- ELAB United States
- REVB United States
- Employees
- ELAB N/A
- REVB N/A
- Industry
- ELAB
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- ELAB
- REVB Health Care
- Exchange
- ELAB Nasdaq
- REVB Nasdaq
- Market Cap
- ELAB 3.2M
- REVB 3.4M
- IPO Year
- ELAB 2023
- REVB N/A
- Fundamental
- Price
- ELAB $6.05
- REVB $1.44
- Analyst Decision
- ELAB
- REVB
- Analyst Count
- ELAB 0
- REVB 0
- Target Price
- ELAB N/A
- REVB N/A
- AVG Volume (30 Days)
- ELAB 45.0K
- REVB 987.4K
- Earning Date
- ELAB 11-13-2025
- REVB 11-07-2025
- Dividend Yield
- ELAB N/A
- REVB N/A
- EPS Growth
- ELAB N/A
- REVB N/A
- EPS
- ELAB N/A
- REVB N/A
- Revenue
- ELAB N/A
- REVB N/A
- Revenue This Year
- ELAB N/A
- REVB N/A
- Revenue Next Year
- ELAB N/A
- REVB N/A
- P/E Ratio
- ELAB N/A
- REVB N/A
- Revenue Growth
- ELAB N/A
- REVB N/A
- 52 Week Low
- ELAB $4.29
- REVB $1.35
- 52 Week High
- ELAB $903.86
- REVB $60.48
- Technical
- Relative Strength Index (RSI)
- ELAB 47.41
- REVB 29.76
- Support Level
- ELAB $5.02
- REVB $1.35
- Resistance Level
- ELAB $5.60
- REVB $1.59
- Average True Range (ATR)
- ELAB 0.39
- REVB 0.10
- MACD
- ELAB 0.07
- REVB 0.02
- Stochastic Oscillator
- ELAB 31.97
- REVB 28.57
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).